Story perspectives

Kodiak Phase 3 Eye-Drug Results Spark 150% Share Surge

By Drooid · Sep 29, 2026, 2:15 AM UTC · How we work

Summary

Kodiak Shares Surge

Kodiak Sciences shares jumped over 150% after Phase 3 eye-drug results.
The Phase 3 trial showed Zenkuda and tabirafusp-ted matched aflibercept’s vision gains.
More than half of patients could receive injections every six months.
Kodiak will file a biologics license application in Q4 and seek FDA approval later this year.
If approved, the treatments could reach market as early as 2027.

Summary

FDA Approves LYTENAVA

FDA approved LYTENAVA (bevacizumab-vikg) for wet AMD on July 24 2026, adding a competitor.
The anti-VEGF market totals $26 billion in 2024, with $15 billion targeted by Kodi’s drugs.
Tabirafusp-ted is a bispecific molecule that blocks VEGF and IL-6 pathways, unlike traditional anti-VEGF agents.
Zenkuda’s mean ocular half-life is about 20 days, roughly three times longer than approved anti-VEGF therapies.
The DAYBREAK trial used OCT-guided “treat-to-dryness” criteria, allowing dosing intervals from 4 to 24 weeks.

History

Historical Context

In June 2006 the FDA approved Genentech’s ranibizumab (Lucentis), the first anti-VEGF drug for wet AMD, prompting intravitreal injections to exceed one million procedures by 2008. Its $2,000-per-dose price and clinical impact set a precedent for longer-acting biologics, and Kodiak Sciences’ 2026 Phase 3 results for Zenkuda and tabirafusp-ted aim to extend dosing intervals and challenge the anti-VEGF market.

1 of 3

Kodiak Shares Surge

Kodiak Sciences shares jumped over 150% after Phase 3 eye-drug results.
The Phase 3 trial showed Zenkuda and tabirafusp-ted matched aflibercept’s vision gains.
More than half of patients could receive injections every six months.
Kodiak will file a biologics license application in Q4 and seek FDA approval later this year.
If approved, the treatments could reach market as early as 2027.

1 / 3